Agile Therapeutics Inc (AGRX) : Proquest Associates Iv scooped up 393,700 additional shares in Agile Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 5,062,363 shares of Agile Therapeutics Inc which is valued at $32.9 Million.Agile Therapeutics Inc makes up approximately 12.47% of Proquest Associates Iv’s portfolio.
Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in AGRX in the latest quarter, The investment management firm added 236,571 additional shares and now holds a total of 374,427 shares of Agile Therapeutics Inc which is valued at $2.4 Million.Royce Associates Lp boosted its stake in AGRX in the latest quarter, The investment management firm added 27,666 additional shares and now holds a total of 325,248 shares of Agile Therapeutics Inc which is valued at $2.1 Million. Agile Therapeutics Inc makes up approx 0.01% of Royce Associates Lp’s portfolio.Blackrock Investment Management boosted its stake in AGRX in the latest quarter, The investment management firm added 5,025 additional shares and now holds a total of 41,600 shares of Agile Therapeutics Inc which is valued at $269,984.
Agile Therapeutics Inc opened for trading at $7.56 and hit $7.99 on the upside on Wednesday, eventually ending the session at $7.7, with a gain of 3.08% or 0.23 points. The heightened volatility saw the trading volume jump to 33,991 shares. Company has a market cap of $221 M.
Agile Therapeutics Inc. is a women’s health specialty pharmaceutical company. The Company is engaged in the development and commercialization of prescription contraceptive products. The Company’s product candidates are designed to provide women with contraceptive options. The Company has developed a transdermal patch technology called Skinfusion. The Company’s lead product candidate Twirla also known as AG200-15 is a once-weekly prescription contraceptive patch in Phase III clinical development. Twirla is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE) which is a synthetic estrogen and levonorgestrel (LNG) which is a type of progestin a synthetic steroid hormone. Twirla is designed using the Company’s Skinfusion technology to consistently deliver both hormones over a seven-day period at levels. The Company is also developing transdermal contraceptive products including AG200-ER AG200-SP and AG890.